This Phase I study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of the company's Tocilizumab biosimilar candidate in comparison to reference products.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/TqFN9aU
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug
https://ift.tt/tzj948y
No comments:
Post a Comment